In Silico Developability and Formulatability Assessment
Accelerate your journey from preclinical to commercialization with Coriolis Pharma’s in silico modelling approach. By combining advanced simulations with experimental expertise, we deliver deeper insights, reduce risk, and save valuable time—right from the first sequence of the molecule.
In Silico Modelling for Developability and Formulatability
Coriolis Pharma’s in silico assessment helps to identify lead candidates with the highest success potential while defining formulation-relevant parameters. This method enables early detection of critical risks, including colloidal and conformational instability, aggregation, high viscosity, and chemical degradation pathways such as oxidation and deamidation—all without the need for physical material.
A standout feature of Coriolis Pharma’s in silico approach is its combination of different computational techniques. Machine learning models are particularly effective at identifying potential stability issues of biologic molecules. On the other hand, mechanistic molecular dynamics models are better suited for examining interactions between the target molecule and various excipients during formulation development, providing insights into potential formulation corridors, i.e. suitable pH-range and type of excipients. This broad scope helps evaluate candidate performance across diverse conditions and formulations.
Model-based analyses for different molecules
Our In Silico Services
-
Identify the most promising molecules and secure competitive advantage early.
-
Predict self-interactions and aggregation risks at high concentrations.
-
Anticipate the influence of formulation parameters on long-term stability.
-
Compare to marketed products, identify outliers, and design robust formulations.
Flexible Engagement Models, Designed to Seamlessly Align with Your Development Needs
Stand-Alone Service
As Integral Part of Development Program
In collaboration with your preferred CDMO
Why Coriolis Pharma?
By integrating computational predictions with experimental validation, Coriolis Pharma provides comprehensive and reliable stability assessments. This synergy ensures data-driven decision-making, customized formulation strategies, and more efficient development timelines.
- Faster and earlier decisions: Gain molecule-specific insights long before material is available for lab testing.
- Risk mitigation: Identify and address potential stability and developability issues early.
- Efficiency: Extract maximum information from a single drug substance sequence without consuming physical material.
- Flexibility: Use as a stand-alone service or as part of a full development program.
Your Phase
Coriolis designs developability and preformulation studies to help you pick the best drug product candidate(s) and/or formulation design from the beginning of your program. This ultimately minimizes program failure risks, speeds up time to market and reduces costs.
